During the pandemic, were great vaccines bad business? A company-by-company review

Taking stock of the drug industry, from the lab to the medicine chest

March 25, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Illustration: Christine Kao/STAT; Photos: Getty STAT+ | During the pandemic, were great vaccines bad business? A company-by-company review When doing good also means doing well: Analyzing revenues, stock prices for major Covid vaccine makers Pfizer, BioNTech, Moderna, AstraZeneca, and more. By Matthew Herper STAT+ | Novo Nordisk to acquire heart disease-focused Cardior Pharmaceuticals in deal worth $1.1 billion The deal, worth up to $1.1 billion, will expand Novo's presence in cardiovascular medicine, as Novo builds on its Wegovy successes. By Andrew Joseph STAT+ | Chick-fil-A drops a 'No Antibiotic Ever' pledge on chicken over supply issues The company will instead switch to chickens raised using antibiotics that are not considered to important to medicines used for human health. By Ed Silverman STAT STAT+ | Patient advocates clash over wisdom of 'approving drugs faster and faster' Accelerated approval has been used to speed drugs to dying patients. But has that come at the expense of better evidence and better drugs? By Jason Mast

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser